What is Ocular Therapeut's earnings per share (EPS)?

Ocular Therapeut (OCUL) reported diluted earnings per share of $-1.42 for fiscal year 2025. This represents a -16.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ocular Therapeut Financials

OCUL

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Ocular Therapeut (OCUL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Ocular Therapeut has an operating margin of -519.8%, meaning the company retains $-520 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -269.6% the prior year.

Growth

Ocular Therapeut's revenue declined 18.5% year-over-year, from $63.7M to $52.0M. This contraction results in a growth score of 3/100.

Leverage

Ocular Therapeut carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 15.39, Ocular Therapeut holds $15.39 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Ocular Therapeut generated -$204.9M in operating cash flow, capex of $12.0M consumed most of it, leaving -$216.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Ocular Therapeut generates a -40.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -61.4% the prior year.

Piotroski F-Score Weak

3/9

Ocular Therapeut passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.77x

For every $1 of reported earnings, Ocular Therapeut generates $0.77 in operating cash flow (-$204.9M OCF vs -$265.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-22.8x

Ocular Therapeut earns $-22.8 in operating income for every $1 of interest expense (-$270.0M vs $11.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$52.0M

YoY-18.5%

5Y CAGR+24.4%

10Y CAGR+40.4%

Ocular Therapeut generated $52.0M in revenue in fiscal year 2025. This represents a decrease of 18.5% from the prior year.

EBITDA

-$265.7M

YoY-58.2%

Ocular Therapeut's EBITDA was -$265.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 58.2% from the prior year.

Net Income

-$265.9M

YoY-37.4%

Ocular Therapeut reported -$265.9M in net income in fiscal year 2025. This represents a decrease of 37.4% from the prior year.

EPS (Diluted)

$-1.42

YoY-16.4%

Ocular Therapeut earned $-1.42 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 16.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$216.9M

YoY-59.5%

Ocular Therapeut generated -$216.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 59.5% from the prior year.

Cash & Debt

$737.1M

YoY+88.0%

5Y CAGR+26.4%

10Y CAGR+37.4%

Ocular Therapeut held $737.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

218M

YoY+38.0%

5Y CAGR+23.4%

10Y CAGR+24.3%

Ocular Therapeut had 218M shares outstanding in fiscal year 2025. This represents an increase of 38.0% from the prior year.

Margins & Returns

Gross Margin

87.4%

YoY-3.8pp

5Y CAGR-0.7pp

10Y CAGR+5.6pp

Ocular Therapeut's gross margin was 87.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.8 percentage points from the prior year.

Operating Margin

-519.8%

YoY-250.2pp

5Y CAGR-158.6pp

10Y CAGR+1662.9pp

Ocular Therapeut's operating margin was -519.8% in fiscal year 2025, reflecting core business profitability. This is down 250.2 percentage points from the prior year.

Net Margin

-511.9%

YoY-208.2pp

5Y CAGR+382.4pp

10Y CAGR+1759.4pp

Ocular Therapeut's net profit margin was -511.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 208.2 percentage points from the prior year.

Return on Equity

-40.6%

YoY+20.7pp

5Y CAGR+163.9pp

10Y CAGR+3.7pp

Ocular Therapeut's ROE was -40.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$197.1M

YoY+54.4%

5Y CAGR+47.0%

10Y CAGR+22.2%

Ocular Therapeut invested $197.1M in research and development in fiscal year 2025. This represents an increase of 54.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$12.0M

YoY+832.5%

5Y CAGR+70.2%

10Y CAGR+21.0%

Ocular Therapeut invested $12.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 832.5% from the prior year.

OCUL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$52.0M-18.5%	$63.7M+9.0%	$58.4M+13.5%	$51.5M+18.3%	$43.5M+150.1%	$17.4M
Cost of Revenue	$6.6M+16.9%	$5.6M+6.5%	$5.3M+16.3%	$4.5M+3.0%	$4.4M+111.5%	$2.1M
Gross Profit	$45.4M-21.9%	$58.1M+9.3%	$53.2M+13.2%	$47.0M+20.0%	$39.1M+155.3%	$15.3M
R&D Expenses	$197.1M+54.4%	$127.6M+109.0%	$61.1M+14.2%	$53.5M+6.7%	$50.1M+74.5%	$28.7M
SG&A Expenses	$64.4M+6.1%	$60.7M+78.7%	$33.9M+5.3%	$32.2M+1.1%	$31.9M+39.5%	$22.9M
Operating Income	-$270.0M-57.2%	-$171.8M-108.5%	-$82.4M-4.7%	-$78.7M-0.8%	-$78.0M-24.2%	-$62.8M
Interest Expense	$11.8M+1234.3%	$887K-92.2%	$11.3M+61.5%	$7.0M+5.3%	$6.7M-1.4%	$6.8M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$265.9M-37.4%	-$193.5M-139.7%	-$80.7M-13.7%	-$71.0M-984.1%	-$6.6M+95.8%	-$155.6M
EPS (Diluted)	$-1.42-16.4%	$-1.22-19.6%	$-1.02-5.2%	$-0.97+1.0%	$-0.98+61.7%	$-2.56

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$13.3M-8.9%	$14.5M+8.1%	$13.5M+25.8%	$10.7M-37.4%	$17.1M+10.7%	$15.4M-6.2%	$16.4M+11.3%	$14.8M
Cost of Revenue	$1.6M-10.1%	$1.8M-8.7%	$1.9M+54.0%	$1.3M+2.6%	$1.2M-21.2%	$1.6M+3.4%	$1.5M+13.8%	$1.3M
Gross Profit	$11.7M-8.7%	$12.8M+10.9%	$11.5M+22.0%	$9.4M-40.5%	$15.9M+14.3%	$13.9M-7.2%	$14.9M+11.0%	$13.4M
R&D Expenses	$50.8M-3.0%	$52.4M+2.5%	$51.1M+19.2%	$42.9M+4.6%	$41.0M+10.6%	$37.1M+28.4%	$28.9M+39.2%	$20.7M
SG&A Expenses	$17.7M+10.2%	$16.0M+11.7%	$14.3M-12.2%	$16.3M+12.0%	$14.6M+19.3%	$12.2M-37.8%	$19.7M+39.0%	$14.1M
Operating Income	-$69.8M-1.5%	-$68.7M-1.6%	-$67.6M-5.8%	-$63.9M-26.4%	-$50.6M-10.0%	-$46.0M-5.5%	-$43.6M-37.9%	-$31.6M
Interest Expense	$2.8M-5.6%	$3.0M-0.5%	$3.0M+1.1%	$3.0M+131.1%	-$9.6M-397.3%	$3.2M+0.9%	$3.2M-21.1%	$4.1M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$64.7M+6.9%	-$69.4M-2.4%	-$67.8M-5.9%	-$64.1M-32.4%	-$48.4M-32.6%	-$36.5M+16.6%	-$43.8M+32.5%	-$64.8M
EPS (Diluted)	N/A	$-0.38+2.6%	$-0.39-2.6%	$-0.38	N/A	$-0.22+15.4%	$-0.26+46.9%	$-0.49

OCUL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$808.1M+76.5%	$457.9M+81.7%	$252.1M+68.8%	$149.3M-27.1%	$204.9M-21.8%	$261.9M
Current Assets	$782.1M+77.4%	$441.0M+89.9%	$232.2M+79.2%	$129.6M-32.2%	$191.3M-22.3%	$246.2M
Cash & Equivalents	$737.1M+88.0%	$392.1M+100.2%	$195.8M+91.4%	$102.3M-37.7%	$164.2M-28.0%	$228.1M
Inventory	$3.6M+17.2%	$3.0M+31.9%	$2.3M+16.8%	$2.0M+57.9%	$1.3M+4.1%	$1.2M
Accounts Receivable	$30.6M-5.4%	$32.4M+23.7%	$26.2M+22.8%	$21.3M+0.9%	$21.1M+72.5%	$12.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$153.7M+7.8%	$142.6M-11.4%	$160.9M+41.3%	$113.9M-2.5%	$116.9M-37.1%	$185.8M
Current Liabilities	$50.8M+22.9%	$41.4M+18.5%	$34.9M+11.2%	$31.4M+19.2%	$26.3M-1.2%	$26.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$654.3M+107.5%	$315.3M+246.0%	$91.1M+157.6%	$35.4M-59.8%	$88.0M+15.6%	$76.1M
Retained Earnings	-$1.2B-29.8%	-$891.1M-27.7%	-$697.6M-13.1%	-$616.8M-13.0%	-$545.8M-1.2%	-$539.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$808.1M+96.7%	$410.9M-9.0%	$451.3M+11.2%	$405.9M-11.4%	$457.9M-6.6%	$490.4M-5.2%	$517.1M-4.1%	$538.9M
Current Assets	$782.1M+102.1%	$387.0M-10.7%	$433.4M+11.8%	$387.7M-12.1%	$441.0M-6.8%	$473.0M-5.1%	$498.6M-4.1%	$519.8M
Cash & Equivalents	$737.1M+113.8%	$344.8M-11.9%	$391.1M+11.9%	$349.7M-10.8%	$392.1M-8.2%	$427.2M-7.1%	$459.7M-4.8%	$482.9M
Inventory	$3.6M+2.2%	$3.5M+14.8%	$3.0M-7.0%	$3.3M+7.5%	$3.0M+26.4%	$2.4M-5.6%	$2.5M-1.0%	$2.6M
Accounts Receivable	$30.6M-0.4%	$30.8M+1.2%	$30.4M+20.6%	$25.2M-22.1%	$32.4M+7.1%	$30.2M0.0%	$30.2M+13.9%	$26.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$153.7M+0.7%	$152.7M+5.0%	$145.4M+3.9%	$140.0M-1.8%	$142.6M+3.1%	$138.3M-0.8%	$139.4M+6.4%	$131.0M
Current Liabilities	$50.8M+3.1%	$49.3M+14.8%	$42.9M+13.2%	$37.9M-8.3%	$41.4M+13.7%	$36.4M+21.3%	$30.0M+23.4%	$24.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$654.3M+153.4%	$258.2M-15.6%	$305.9M+15.0%	$265.9M-15.7%	$315.3M-10.4%	$352.0M-6.8%	$377.7M-7.4%	$408.0M
Retained Earnings	-$1.2B-5.9%	-$1.1B-6.8%	-$1.0B-7.1%	-$955.1M-7.2%	-$891.1M-5.7%	-$842.7M-4.5%	-$806.2M-5.7%	-$762.4M

OCUL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$204.9M-52.1%	-$134.7M-91.8%	-$70.2M-17.8%	-$59.6M+9.1%	-$65.5M-22.4%	-$53.6M
Capital Expenditures	$12.0M+832.5%	$1.3M-78.8%	$6.1M+63.8%	$3.7M+211.1%	$1.2M+42.0%	$841K
Free Cash Flow	-$216.9M-59.5%	-$136.0M-78.1%	-$76.3M-20.5%	-$63.3M+5.1%	-$66.7M-22.7%	-$54.4M
Investing Cash Flow	-$11.9M-822.4%	-$1.3M+78.8%	-$6.1M-63.8%	-$3.7M-211.1%	-$1.2M-42.0%	-$841K
Financing Cash Flow	$561.7M+69.1%	$332.1M+95.6%	$169.8M+11580.1%	$1.5M-49.0%	$2.9M-98.7%	$228.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$54.2M-6.9%	-$50.7M+8.2%	-$55.2M-23.7%	-$44.7M-13.3%	-$39.4M-7.9%	-$36.6M-47.4%	-$24.8M+26.8%	-$33.9M
Capital Expenditures	$2.8M-52.6%	$6.0M+381.4%	$1.2M-35.6%	$1.9M+856.9%	$202K+127.0%	$89K-88.0%	$742K+191.0%	$255K
Free Cash Flow	-$57.1M-0.7%	-$56.7M-0.4%	-$56.5M-21.2%	-$46.6M-17.6%	-$39.6M-8.1%	-$36.6M-43.5%	-$25.5M+25.2%	-$34.1M
Investing Cash Flow	-$2.8M+52.6%	-$6.0M-437.5%	-$1.1M+42.3%	-$1.9M-856.9%	-$202K-127.0%	-$89K+88.0%	-$742K-191.0%	-$255K
Financing Cash Flow	$449.4M+4239.3%	$10.4M-89.4%	$97.8M+2238.2%	$4.2M-7.3%	$4.5M+8.0%	$4.2M+90.3%	$2.2M-99.3%	$321.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OCUL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	87.4%-3.8pp	91.2%+0.2pp	91.0%-0.2pp	91.2%+1.3pp	89.9%+1.9pp	88.0%
Operating Margin	-519.8%-250.2pp	-269.6%-128.6pp	-141.0%+11.8pp	-152.7%+26.6pp	-179.3%+181.8pp	-361.1%
Net Margin	-511.9%-208.2pp	-303.7%-165.5pp	-138.1%-0.2pp	-137.9%-122.9pp	-15.1%+879.2pp	-894.3%
Return on Equity	-40.6%+20.7pp	-61.4%+27.2pp	-88.6%+112.2pp	-200.8%-193.3pp	-7.4%+197.1pp	-204.5%
Return on Assets	-32.9%+9.3pp	-42.3%-10.2pp	-32.0%+15.6pp	-47.6%-44.4pp	-3.2%+56.2pp	-59.4%
Current Ratio	15.39+4.7	10.66+4.0	6.66+2.5	4.13-3.1	7.26-2.0	9.23
Debt-to-Equity	0.23-0.2	0.45-1.3	1.77-1.5	3.22+1.9	1.33-1.1	2.44
FCF Margin	-417.5%-204.1pp	-213.4%-82.8pp	-130.6%-7.6pp	-123.0%+30.4pp	-153.4%+159.2pp	-312.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	88.0%+0.2pp	87.8%+2.2pp	85.6%-2.6pp	88.2%-4.6pp	92.8%+2.9pp	89.9%-0.9pp	90.8%-0.2pp	91.0%
Operating Margin	-526.5%-54.2pp	-472.3%+30.2pp	-502.6%+94.9pp	-597.5%-301.4pp	-296.1%+2.1pp	-298.2%-33.1pp	-265.1%-51.1pp	-214.0%
Net Margin	-488.0%-10.7pp	-477.3%+26.6pp	-503.9%+94.9pp	-598.7%-315.5pp	-283.3%-46.7pp	-236.6%+29.7pp	-266.3%+172.7pp	-438.9%
Return on Equity	-9.9%+17.0pp	-26.9%-4.7pp	-22.2%+1.9pp	-24.1%-8.8pp	-15.3%-5.0pp	-10.4%+1.2pp	-11.6%+4.3pp	-15.9%
Return on Assets	-8.0%+8.9pp	-16.9%-1.9pp	-15.0%+0.8pp	-15.8%-5.2pp	-10.6%-3.1pp	-7.4%+1.0pp	-8.5%+3.6pp	-12.0%
Current Ratio	15.39+7.5	7.85-2.2	10.09-0.1	10.22-0.4	10.66-2.3	13.01-3.6	16.64-4.8	21.39
Debt-to-Equity	0.23-0.4	0.59+0.1	0.48-0.1	0.53+0.1	0.45+0.1	0.39+0.0	0.37+0.0	0.32
FCF Margin	-430.9%-40.9pp	-390.0%+29.7pp	-419.7%+16.0pp	-435.6%-203.6pp	-232.0%+5.6pp	-237.6%-82.2pp	-155.4%+75.7pp	-231.1%

Similar Companies

Tarsus Pharmaceuticals, Inc. TARS

$2.8B

Beam Therapeutics Inc. BEAM

$2.3B

Liquidia Corporation LQDA

$3.1B

Belite Bio, Inc BLTE

$6.0B

Travere Therapeutics Inc TVTX

$2.5B

Frequently Asked Questions

What is Ocular Therapeut's annual revenue?

Ocular Therapeut (OCUL) reported $52.0M in total revenue for fiscal year 2025. This represents a -18.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ocular Therapeut's revenue growing?

Ocular Therapeut (OCUL) revenue declined by 18.5% year-over-year, from $63.7M to $52.0M in fiscal year 2025.

Is Ocular Therapeut profitable?

No, Ocular Therapeut (OCUL) reported a net income of -$265.9M in fiscal year 2025, with a net profit margin of -511.9%.

What is Ocular Therapeut's EBITDA?

Ocular Therapeut (OCUL) had EBITDA of -$265.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ocular Therapeut's gross margin?

Ocular Therapeut (OCUL) had a gross margin of 87.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Ocular Therapeut's operating margin?

Ocular Therapeut (OCUL) had an operating margin of -519.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ocular Therapeut's net profit margin?

Ocular Therapeut (OCUL) had a net profit margin of -511.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ocular Therapeut's return on equity (ROE)?

Ocular Therapeut (OCUL) has a return on equity of -40.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ocular Therapeut's free cash flow?

Ocular Therapeut (OCUL) generated -$216.9M in free cash flow during fiscal year 2025. This represents a -59.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ocular Therapeut's operating cash flow?

Ocular Therapeut (OCUL) generated -$204.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ocular Therapeut's total assets?

Ocular Therapeut (OCUL) had $808.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ocular Therapeut's capital expenditures?

Ocular Therapeut (OCUL) invested $12.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Ocular Therapeut spend on research and development?

Ocular Therapeut (OCUL) invested $197.1M in research and development during fiscal year 2025.

How many shares does Ocular Therapeut have outstanding?

Ocular Therapeut (OCUL) had 218M shares outstanding as of fiscal year 2025.

What is Ocular Therapeut's current ratio?

Ocular Therapeut (OCUL) had a current ratio of 15.39 as of fiscal year 2025, which is generally considered healthy.

What is Ocular Therapeut's debt-to-equity ratio?

Ocular Therapeut (OCUL) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ocular Therapeut's return on assets (ROA)?

Ocular Therapeut (OCUL) had a return on assets of -32.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ocular Therapeut's cash runway?

Based on fiscal year 2025 data, Ocular Therapeut (OCUL) had $737.1M in cash against an annual operating cash burn of $204.9M. This gives an estimated cash runway of approximately 43 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Ocular Therapeut's Piotroski F-Score?

Ocular Therapeut (OCUL) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ocular Therapeut's earnings high quality?

Ocular Therapeut (OCUL) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ocular Therapeut cover its interest payments?

Ocular Therapeut (OCUL) has an interest coverage ratio of -22.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ocular Therapeut?

Ocular Therapeut (OCUL) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.